O'Shaughnessy Asset Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

O'Shaughnessy Asset Management’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-321	Closed	-$1K	–	2825
2021 Q3	$1K	Sell	321 -85	-21%	-$232	﹤0.01%	2694
2021 Q2	$1K	Hold	406	–	–	﹤0.01%	2555
2021 Q1	$1K	Sell	406 -236	-37%	-$770	﹤0.01%	2352
2020 Q4	$2K	Buy	642 +506	+372%	+$1.68K	﹤0.01%	1878
2020 Q3	$0	Hold	136	–	–	﹤0.01%	2104
2020 Q2	$0	Buy	+136	New	+$144	﹤0.01%	1988

Other funds holding CTIC

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

ACM

Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

O'Shaughnessy Asset Management's CTIC Position: Q4 2021 in Review

O'Shaughnessy Asset Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q4 2021, closing a stake of 321 shares — an estimated $1K sold.

O'Shaughnessy Asset Management first reported a position in CTIC in Q2 2020 and held it in 6 quarters. The position peaked at $2K in Q4 2020. 63 funds tracked by Wall St. Rank hold CTIC as of Q4 2021.

O'Shaughnessy Asset Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q4 2021 after selling out during the quarter.
O'Shaughnessy Asset Management sold 321 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2021, an estimated $1K.
O'Shaughnessy Asset Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2020 and held it in 6 quarters.
O'Shaughnessy Asset Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $2K in Q4 2020.
63 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2021.

Based on O'Shaughnessy Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.